Order Article Reprints

Kitonsa J, Serwanga J, Cheeseman HM, Abaasa A, Lunkuse JF, Ruzagira E, Kato L, Nambaziira F, Oluka GK, Gombe B, et al. Safety and Immunogenicity of a Modified Self-Amplifying Ribonucleic Acid (saRNA) Vaccine Encoding SARS-CoV-2 Spike Glycoprotein in SARS-CoV-2 Seronegative and Seropositive Ugandan Individuals. Vaccines. 2025; 13(6):553. https://doi.org/10.3390/vaccines13060553

Kitonsa, Jonathan, Jennifer Serwanga, Hannah M. Cheeseman, Andrew Abaasa, Jane Frances Lunkuse, Eugene Ruzagira, Laban Kato, Florence Nambaziira, Gerald Kevin Oluka, Ben Gombe, and et al. 2025. "Safety and Immunogenicity of a Modified Self-Amplifying Ribonucleic Acid (saRNA) Vaccine Encoding SARS-CoV-2 Spike Glycoprotein in SARS-CoV-2 Seronegative and Seropositive Ugandan Individuals" Vaccines 13, no. 6: 553. https://doi.org/10.3390/vaccines13060553

Kitonsa, J., Serwanga, J., Cheeseman, H. M., Abaasa, A., Lunkuse, J. F., Ruzagira, E., Kato, L., Nambaziira, F., Oluka, G. K., Gombe, B., Jackson, S., Ssebwana, J. K., McFarlane, L. R., Joseph, S., Pierce, B. F., Shattock, R. J., & Kaleebu, P. (2025). Safety and Immunogenicity of a Modified Self-Amplifying Ribonucleic Acid (saRNA) Vaccine Encoding SARS-CoV-2 Spike Glycoprotein in SARS-CoV-2 Seronegative and Seropositive Ugandan Individuals. Vaccines, 13(6), 553. https://doi.org/10.3390/vaccines13060553